Long-term stability of Alzheimer's disease biomarker proteins in cerebrospinal fluid

Manuscript Number: 

11-0329R1

Author(s): 
Hermann Esselmann, Lutz Frölich, Frank L. Heppner, Isabella Heuser, Frank Jessen, Christian Luckhaus, Wolfgang Maier, Oliver Peters, Stefan Prokop, Eckart Ruther, Carola G. Schipke, Stefan J. Teipel, Jens Wiltfang

Disclosures

Hermann Esselmann

  • Nothing to Disclose

Lutz Frölich

  • Nothing to Disclose

Frank L. Heppner

  • Lecture Fees:
    Invited talks for Novartis

Isabella Heuser

  • Consulting Fees:
    GE Healthcare Astra Zeneca Novartis Bayer Healthcare

Frank Jessen

  • Nothing to Disclose

Christian Luckhaus

  • Nothing to Disclose

Wolfgang Maier

  • Consulting Fees:
    I have received research grants from the following companies respectively is member of the Advisory Boards or draws a fee speech from: Astra Zeneca, Bayer Vital, Böhringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, General Electrics, Janssen-Cilag, Lundbeck, Merck, Merz, Novartis, Pfizer, Sanofi-Aventis, Schering

Oliver Peters

  • Lecture Fees:
    Bayer-Schering, Novartis, Medivation

Stefan Prokop

  • Nothing to Disclose

Eckart Ruther

  • Consulting Fees:
    Lilly, BMS,Servier,Merz, Lundbeck, Astra-Zeneca
    Lecture Fees:
    Lundbeck, Lilly, BMS
    Grants
    • Agency: 
      Lilly
      Dates: 
      2009
    • Agency: 
      Astra Zeneca
      Dates: 
      2009
    • Agency: 
      BMS
      Dates: 
      2009

Carola G. Schipke

  • Nothing to Disclose

Stefan J. Teipel

  • Nothing to Disclose

Jens Wiltfang

  • Nothing to Disclose